Skip to main content

Advertisement

Table 3 Performance characteristics of NEAT and clinico-pathological scores

From: Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

Cohort Percentage NRI (95% CI) HR (95% CI)
NEAT vs IMDC NEAT vs MSKCC+ NEAT IMDC MSKCC
Validation 7.1a (–24.8, 39.0) 25.4b (–25.7, 76.5) 37.89 (4.1, 353.8) 7.317a (1.54, 34.69) 14.39b (1.24, 165.7)
Development 25.0 (–34.8, 84.8) 23.3 (–28.3, 74.9) 10.649 (1.35, 84.08) 1.378 (0.44, 4.36) 3.577 (1.00, 12.85)
  1. NRI net reclassification improvement, HR Hazard ratio, NEAT N-cadherin EPCAM Age mTOR multivariate model, IMDC International Metastatic Database Consortium, MSKCC Memorial Sloan Kettering Cancer Center
  2. Values reflect assignment of either high risk or low risk status (methods)
  3. a n = 20 due to data availability
  4. b n = 16 due to data availability